218 related articles for article (PubMed ID: 38139340)
1. CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.
Aragón-Serrano L; Carrillo-Serradell L; Planells-Romeo V; Isamat M; Velasco-de Andrés M; Lozano F
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139340
[TBL] [Abstract][Full Text] [Related]
2. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract][Full Text] [Related]
3. Modulation of CD6 function through interaction with Galectin-1 and -3.
Escoda-Ferran C; Carrasco E; Caballero-Baños M; Miró-Julià C; Martínez-Florensa M; Consuegra-Fernández M; Martínez VG; Liu FT; Lozano F
FEBS Lett; 2014 Aug; 588(17):2805-13. PubMed ID: 24945728
[TBL] [Abstract][Full Text] [Related]
4. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry.
Bowen MA; Bajorath J; Siadak AW; Modrell B; Malacko AR; Marquardt H; Nadler SG; Aruffo A
J Biol Chem; 1996 Jul; 271(29):17390-6. PubMed ID: 8663238
[TBL] [Abstract][Full Text] [Related]
5. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions.
Bowen MA; Aruffo AA; Bajorath J
Proteins; 2000 Aug; 40(3):420-8. PubMed ID: 10861932
[TBL] [Abstract][Full Text] [Related]
6. Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
Casadó-Llombart S; Ajami T; Consuegra-Fernández M; Carreras E; Aranda F; Armiger N; Alcaraz A; Mengual L; Lozano F
Prostate; 2022 Oct; 82(14):1331-1337. PubMed ID: 35767366
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.
Ibáñez A; Sarrias MR; Farnós M; Gimferrer I; Serra-Pagès C; Vives J; Lozano F
J Immunol; 2006 Jul; 177(2):1152-9. PubMed ID: 16818773
[TBL] [Abstract][Full Text] [Related]
8. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
9. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.
Bowen MA; Patel DD; Li X; Modrell B; Malacko AR; Wang WC; Marquardt H; Neubauer M; Pesando JM; Francke U
J Exp Med; 1995 Jun; 181(6):2213-20. PubMed ID: 7760007
[TBL] [Abstract][Full Text] [Related]
10. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site.
Whitney GS; Starling GC; Bowen MA; Modrell B; Siadak AW; Aruffo A
J Biol Chem; 1995 Aug; 270(31):18187-90. PubMed ID: 7543097
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted effects of soluble human CD6 in experimental cancer models.
Simões IT; Aranda F; Casadó-Llombart S; Velasco-de Andrés M; Català C; Álvarez P; Consuegra-Fernández M; Orta-Mascaró M; Merino R; Merino J; Alberola-Ila J; González-Aseguinolaza G; Carreras E; Martínez V; Lozano F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217757
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic activated leukocyte cell adhesion molecule induces CD6
Qian Q; Cui N; Huang B; Zhao Y; Liu Q; Hu M; Li B; Wang Q; Miao Q; You Z; Ma X; Tang R
Front Immunol; 2022; 13():967944. PubMed ID: 36159854
[TBL] [Abstract][Full Text] [Related]
13. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166.
Hassan NJ; Barclay AN; Brown MH
Eur J Immunol; 2004 Apr; 34(4):930-40. PubMed ID: 15048703
[TBL] [Abstract][Full Text] [Related]
14. Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CE; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Res Sq; 2023 Oct; ():. PubMed ID: 37886483
[TBL] [Abstract][Full Text] [Related]
15. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
Nair P; Melarkode R; Rajkumar D; Montero E
Clin Exp Immunol; 2010 Oct; 162(1):116-30. PubMed ID: 20726988
[TBL] [Abstract][Full Text] [Related]
16. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
17. Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM.
Skonier JE; Bowen MA; Emswiler J; Aruffo A; Bajorath J
Biochemistry; 1996 Sep; 35(38):12287-91. PubMed ID: 8823162
[TBL] [Abstract][Full Text] [Related]
18. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes.
Singer NG; Mitra R; Lialios F; Richardson BC; Marks RM; Pesando JM; Fox DA; Nickoloff BJ
Immunol Lett; 1997 Jun; 58(1):9-14. PubMed ID: 9436462
[TBL] [Abstract][Full Text] [Related]
19. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
Alonso R; Huerta V; de Leon J; Piedra P; Puchades Y; Guirola O; Chinea G; Montero E
Hybridoma (Larchmt); 2008 Aug; 27(4):291-301. PubMed ID: 18707547
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents.
Velasco-de Andrés M; Casadó-Llombart S; Català C; Leyton-Pereira A; Lozano F; Aranda F
Cells; 2020 Dec; 9(12):. PubMed ID: 33287301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
